Boyd G W
Aust N Z J Med. 1976 Aug;6(3 Suppl):4-13. doi: 10.1111/j.1445-5994.1976.tb03327.x.
The aliphatic partial structure common to the beta-receptor antagonists leads to similar products of their biotransformation. The main qualitative and quantitative differences of the metabolism of the compounds of this class, however, rest in the nature of their aromatic or heterocyclic substituents. The physico-chemical properties of the beta-blockers appear to be predominantly responsible for the extent of metabolic degradation and for the distribution in the body, especially for the binding to proteins. As a consequence of their different biological disposition the clinically relevant systemic bioavailabilities of the various beta-blockers from oral doses differ drastically. Practolol maintains an extreme position among all other compounds: It is most hydrophilic, it is not bound to proteins, it is metabolized least, but cleared renally in unchanged form to 85% of the dose. Despite its extremely high systemic bioavailability, relatively high daily doses were required for therapy. The receptor sensitivity for practolol has been rated 2 to 3 powers of 1- lower than of propranolol. Comparative pharmacokinetic assessment of beta-receptor antagonists requires quantitative analytical data in clinically representative groups of patients. This has been demonstrated by respective studies with oxprenolol. The intra- and inter-individual systemic bioavailability, the differential analysis of plasma and erythrocytes, the multiexponential elimination kinetics, and their possible dependence on the dose have been studied as clinically relevant pharmacokinetic characteristics. The continuing attempt of the pharmaceutical industry to optimize the properties of beta-blockers also has taken advantage of the slow release principle in oral dosage forms as shown by the example of oxprenolol. The beta-receptor antagonists belong to one of the youngest classes of pharmaceuticals. Pharmacokinetic and metabolic data for the different representatives of this class have been generated in different laboratories with different approaches and different techniques. Therefore, full comparative documentation is still incomplete.
β受体拮抗剂的脂肪族部分结构导致它们的生物转化产物相似。然而,这类化合物代谢的主要定性和定量差异在于其芳香族或杂环取代基的性质。β受体阻滞剂的物理化学性质似乎主要决定了代谢降解的程度和在体内的分布,尤其是与蛋白质的结合。由于它们不同的生物处置方式,各种β受体阻滞剂口服剂量后的临床相关全身生物利用度差异很大。醋丁洛尔在所有其他化合物中处于极端位置:它最亲水,不与蛋白质结合,代谢最少,但以原形经肾脏清除,占剂量的85%。尽管其全身生物利用度极高,但治疗仍需要相对较高的日剂量。醋丁洛尔的受体敏感性比普萘洛尔低2至3个数量级。β受体拮抗剂的比较药代动力学评估需要临床代表性患者群体的定量分析数据。氧烯洛尔的相关研究已证明了这一点。已将个体内和个体间全身生物利用度、血浆和红细胞的差异分析、多指数消除动力学及其可能对剂量的依赖性作为临床相关药代动力学特征进行了研究。制药行业持续尝试优化β受体阻滞剂的性质,也利用了口服剂型的缓释原理,氧烯洛尔的例子就表明了这一点。β受体拮抗剂属于最年轻的一类药物。这类不同代表物的药代动力学和代谢数据是在不同实验室采用不同方法和技术生成的。因此,完整的比较文献仍然不完整。